DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
Minghui’s MHB088C will soon start phase 3 in China.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.